NCT03639714 2023-09-13A Study of a Personalized Neoantigen Cancer VaccineGritstone bio, Inc.Phase 1/2 Completed29 enrolled
NCT03953235 2023-09-13A Study of a Personalized Cancer Vaccine Targeting Shared NeoantigensGritstone bio, Inc.Phase 1/2 Completed39 enrolled
NCT03445533 2022-11-08A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory MelanomaIdera Pharmaceuticals, Inc.Phase 3 Terminated481 enrolled 22 charts